NEW YORK, Jan. 08, 2024 (Korea Bizwire) – Citeline, a Norstella company providing robust data and expert business intelligence to the pharmaceutical industry, will offer exclusive access to insights from the 42nd Annual J.P. Morgan Healthcare Conference (JPM) Jan. 8–11, 2024 in San Francisco.
JPM, the industry’s largest healthcare investment symposium, provides a detailed look at the state of the industry today and where it is headed in the coming year. This invite-only event brings together global industry leaders, emerging fast-growth companies, technology creators, and members of the investment community to discuss the latest market trends and innovations.
Citeline will provide daily updates and insights from JPM24. Those who register for updates will receive a top-level summary (via Scrip) and a detailed breakdown of what was announced in each company’s presentations (via Biomedtracker).
Key industry experts from Citeline attending JPM include analysts and reporters from Citeline’s Scrip and Biomedtracker publications. Further Citeline coverage will also be provided by journalists from Medtech Insight.
Following the conference, Citeline will host a webinar with a panel of industry experts to discuss key JPM takeaways with an outlook for 2024. The webinar will take place Feb. 6.
Sign up for access to Citeline’s JPM updates. For access to Scrip and Biomedtracker, visit Citeline.
About Citeline
Citeline, a Norstella company, powers a full suite of complementary business intelligence offerings to meet the evolving needs of life science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial, and regulatory-related decisions and create real-world opportunities for growth.
Citeline’s global teams of analysts, journalists, and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts, and more. For more information on one of the world’s most trusted health science partners, visit Citeline and follow on LinkedIn and X (formerly Twitter).
Citeline PR contact:
Diffusion PR for Citeline
citeline@diffusionpr.com
(213) 318-4500
Source: Caerus Us 1 Inc. (dba Citeline) via GLOBE NEWSWIRE